Search Videos by Topic or Participant
Browse by Series:

Emerging Strategies in the Treatment of ALL

Panelists: John C. Byrd, MD, Ohio State University; Dan Douer, MD, MSKCC;Stephen P. Hunger, MD, University of Colorado; Brad S. Kahl, MD, University
Published: Monday, Feb 03, 2014
For High-Definition, Click
Several new therapies have recently become available or are under exploration for the treatment of patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL). In 2012 the FDA granted accelerated approval for vincristine sulfate liposome injection (Marqibo) for the treatment of adult patients with Ph-negative ALL in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.

In addition to this therapy, the many T cells therapies coming down the line are extremely exciting, panelists believe. Moreover, the cytokine release syndrome of the CAR therapies or the infusion-related status epilepticus of blinatumomab appear manageable, even outside of academic settings. Additionally, the technology utilized to measure response has increased greatly with the introduction of minimal residual disease tests.
Slider Left
Slider Right
For High-Definition, Click
Several new therapies have recently become available or are under exploration for the treatment of patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL). In 2012 the FDA granted accelerated approval for vincristine sulfate liposome injection (Marqibo) for the treatment of adult patients with Ph-negative ALL in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.

In addition to this therapy, the many T cells therapies coming down the line are extremely exciting, panelists believe. Moreover, the cytokine release syndrome of the CAR therapies or the infusion-related status epilepticus of blinatumomab appear manageable, even outside of academic settings. Additionally, the technology utilized to measure response has increased greatly with the introduction of minimal residual disease tests.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Publication Bottom Border
Border Publication
x